FDA approves nivolumab for esophageal squamous cell carcinoma
Hematology / Oncology News (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
PRINCETON, N.J.--(BUSINESS WIRE) June 10, 2020 Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurrent... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 10, 2020 Category: Drugs & Pharmacology Source Type: news
SARS-CoV-2 Detected in Tongue Squamous Cell Carcinoma Surgical Specimen SARS-CoV-2 Detected in Tongue Squamous Cell Carcinoma Surgical Specimen
SARS-CoV-2 was detected in tissue specimens from a surgically resected tongue squamous cell carcinoma of a patient who later developed COVID-19, according to a case report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - May 26, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Many Patients with Anal Cancer Experienced Chemoradiation Therapy Interruption and Noncompletion
A recent study published in JAMA Oncology revealed that quality improvement initiatives are necessary to optimize treatment and lessen chemotherapy interruption and noncompletion rates among patients with squamous cell anal carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 4, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Erratum for the Research Article: "Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis" by X. Ding, H. Pan, J. Li, Q. Zhong, X. Chen, S. M. Dry, C.-Y. Wang
(Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - April 20, 2020 Category: Science Tags: STKE Errata Source Type: news
How Mohs surgery is used to fight skin cancer: Mayo Clinic Radio Health Minute
Mohs surgery is used to treat the most common skin cancers, basal cell carcinoma and squamous cell carcinoma, as well as some kinds of melanoma. It's especially useful for skin cancers located in areas where it's important to preserve as much healthy skin as possible, such as around the eyes, ears, nose and mouth. In [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 8, 2020 Category: Databases & Libraries Source Type: news
Moffitt identifies novel therapeutic targets in cutaneous squamous cell carcinoma
(H. Lee Moffitt Cancer Center& Research Institute) Researchers at Moffitt Cancer Center want to devise better therapeutic strategies for patients with cutaneous squamous cell carcinoma (cuSCC) by improving their understanding of how the disease develops. In a new article published online ahead of print in the journal Cancer Research, Moffitt scientists report on their identification of potential therapeutic targets for cuSCC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news
April's SLAS Discovery now available
(SLAS (Society for Laboratory Automation and Screening)) 'Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines' Leads April's SLAS Discovery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 23, 2020 Category: Cancer & Oncology Source Type: news
An Update on Systemic Therapy for Penile Cancer An Update on Systemic Therapy for Penile Cancer
Learn about the most recent advancements in systemic therapy for penile squamous cell carcinoma.Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 17, 2020 Category: Consumer Health News Tags: Urology Journal Article Source Type: news
Race, Insurance Status Linked to Lower Cancer Survival
MONDAY, March 16, 2020 -- Nonwhite, uninsured patients with clinically favorable human papillomavirus (HPV)-associated squamous cell carcinoma of the head and neck (SCCHN) have higher mortality than their white peers, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 16, 2020 Category: Pharmaceuticals Source Type: news
Rare driver mutations disrupt NOTCH signaling to promote squamous cell carcinoma
(American Association for the Advancement of Science) Head and neck squamous cell carcinoma (HNSCC) -- a group of cancers that affect the the mouth, nose and throat -- is a disease driven by mutations in the NOTCH tumor suppressor signaling pathway, according to a new study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2020 Category: Cancer & Oncology Source Type: news
Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling
In most human cancers, only a few genes are mutated at high frequencies; most are mutated at low frequencies. The functional consequences of these recurrent but infrequent "long tail" mutations are often unknown. We focused on 484 long tail genes in head and neck squamous cell carcinoma (HNSCC) and used in vivo CRISPR to screen for genes that, upon mutation, trigger tumor development in mice. Of the 15 tumor-suppressor genes identified, ADAM10 and AJUBA suppressed HNSCC in a haploinsufficient manner by promoting NOTCH receptor signaling. ADAM10 and AJUBA mutations or monoallelic loss occur in 28% of human HNSCC cases and a...
Source: ScienceNOW - March 11, 2020 Category: Science Authors: Loganathan, S. K., Schleicher, K., Malik, A., Quevedo, R., Langille, E., Teng, K., Oh, R. H., Rathod, B., Tsai, R., Samavarchi-Tehrani, P., Pugh, T. J., Gingras, A.-C., Schramek, D. Tags: Genetics, Medicine, Diseases reports Source Type: news
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[1] Cu...
Source: Johnson and Johnson - March 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Tracking down false parkers in cancer cells
(University of W ü rzburg) In squamous cell carcinoma, a protein ensures that unneeded proteins are no longer disposed of. A research team at the University of W ü rzburg has switched off this protein for the first time. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 10, 2020 Category: Cancer & Oncology Source Type: news
Radiation/immunotherapy combo shows promise for recurrent/metastatic head and neck cancers
(American Society for Radiation Oncology) A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The combination of radiation and pembrolizumab may offer a new treatment option for patients who are ineligible for cisplatin chemotherapy, part of standard treatment for the disease. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news
